Predicted sensitivity to endocrine therapy for stage II-III hormone receptor-positive and HER2-negative (HR+/HER2-) breast cancer before chemo-endocrine therapy
化疗-内分泌治疗前,预测II-III期激素受体阳性、HER2阴性(HR+/HER2-)乳腺癌对内分泌治疗的敏感性
期刊:Annals of Oncology
影响因子:65.4
doi:10.1016/j.annonc.2021.02.011
Du, L; Yau, C; Brown-Swigart, L; Gould, R; Krings, G; Hirst, G L; Bedrosian, I; Layman, R M; Carter, J M; Klein, M; Venters, S; Shad, S; van der Noordaa, M; Chien, A J; Haddad, T; Isaacs, C; Pusztai, L; Albain, K; Nanda, R; Tripathy, D; Liu, M C; Boughey, J; Schwab, R; Hylton, N; DeMichele, A; Perlmutter, J; Yee, D; Berry, D; Van't Veer, L; Valero, V; Esserman, L J; Symmans, W F